These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1490 related items for PubMed ID: 29059158

  • 1. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
    Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.
    Oncogene; 2018 Feb 08; 37(6):821-832. PubMed ID: 29059158
    [Abstract] [Full Text] [Related]

  • 2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 3. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
    Yadav V, Burke TF, Huber L, Van Horn RD, Zhang Y, Buchanan SG, Chan EM, Starling JJ, Beckmann RP, Peng SB.
    Mol Cancer Ther; 2014 Oct 07; 13(10):2253-63. PubMed ID: 25122067
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.
    Cancer Cell; 2015 Sep 14; 28(3):384-98. PubMed ID: 26343583
    [Abstract] [Full Text] [Related]

  • 5. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
    Zhao X, Wang X, Fang L, Lan C, Zheng X, Wang Y, Zhang Y, Han X, Liu S, Cheng K, Zhao Y, Shi J, Guo J, Hao J, Ren H, Nie G.
    Cancer Lett; 2017 Aug 28; 402():61-70. PubMed ID: 28576749
    [Abstract] [Full Text] [Related]

  • 6. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer In Vitro and In Vivo.
    Naz S, Sowers A, Choudhuri R, Wissler M, Gamson J, Mathias A, Cook JA, Mitchell JB.
    Clin Cancer Res; 2018 Aug 15; 24(16):3994-4005. PubMed ID: 29716919
    [Abstract] [Full Text] [Related]

  • 7. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS, Jung M, Kang HN, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC.
    Oncogene; 2017 Jun 08; 36(23):3334-3345. PubMed ID: 28092667
    [Abstract] [Full Text] [Related]

  • 8. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
    Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB.
    Cancer Discov; 2016 Mar 08; 6(3):300-15. PubMed ID: 26732095
    [Abstract] [Full Text] [Related]

  • 9. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
    Miyauchi S, Shien K, Takeda T, Araki K, Nakata K, Miura A, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Suzawa K, Yamamoto H, Okazaki M, Soh J, Tomida S, Yamane M, Sakaguchi M, Toyooka S.
    Anticancer Res; 2020 May 08; 40(5):2667-2673. PubMed ID: 32366411
    [Abstract] [Full Text] [Related]

  • 10. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
    Zhou J, Zhang S, Chen X, Zheng X, Yao Y, Lu G, Zhou J.
    Cancer Lett; 2017 Nov 01; 408():130-137. PubMed ID: 28866094
    [Abstract] [Full Text] [Related]

  • 11. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
    Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE.
    Mol Cancer Ther; 2021 Oct 01; 20(10):2049-2060. PubMed ID: 34376578
    [Abstract] [Full Text] [Related]

  • 12. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK.
    Oncotarget; 2017 Jul 04; 8(27):43678-43691. PubMed ID: 28620137
    [Abstract] [Full Text] [Related]

  • 13. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, Gelbert LM, Shannon HE, Sanchez-Martinez C, De Dios A.
    Drug Metab Dispos; 2015 Sep 04; 43(9):1360-71. PubMed ID: 26149830
    [Abstract] [Full Text] [Related]

  • 14. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.
    J Med Chem; 2015 May 28; 58(10):4165-79. PubMed ID: 25965804
    [Abstract] [Full Text] [Related]

  • 15. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
    Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH.
    Cancer Biol Ther; 2013 Jul 28; 14(7):597-605. PubMed ID: 23792647
    [Abstract] [Full Text] [Related]

  • 16. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R, Kishino E, Saitoh W, Koike Y, Kurebayashi J.
    Breast Cancer; 2021 Jan 28; 28(1):206-215. PubMed ID: 32860163
    [Abstract] [Full Text] [Related]

  • 17. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.
    Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.
    Clin Cancer Res; 2017 Sep 15; 23(18):5547-5560. PubMed ID: 28611205
    [Abstract] [Full Text] [Related]

  • 18. Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers.
    Yadav V, Chen SH, Yue YG, Buchanan S, Beckmann RP, Peng SB.
    Pharmacol Ther; 2015 May 15; 149():139-49. PubMed ID: 25550229
    [Abstract] [Full Text] [Related]

  • 19. Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6-Cyclin D-Rb pathway.
    Wang D, Bao H.
    Cancer Chemother Pharmacol; 2022 Jan 15; 89(1):31-40. PubMed ID: 34655298
    [Abstract] [Full Text] [Related]

  • 20. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M, Yatim SMJM, Chen Y, Li J, Gong M, Jiang X, Zhang F, Zheng J, Wu X, Yu Q.
    Oncogene; 2017 Aug 31; 36(35):4975-4986. PubMed ID: 28459468
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 75.